NCT05856890View on ClinicalTrials.gov

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

December 1, 2027

Study Completion Date

March 30, 2028

Conditions
Hepatitis b VirusHepatitis B
Interventions
BIOLOGICAL

HepB mAb19

"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."

OTHER

Sterile Saline

Placebo will be normal sterile saline (NaCl 0.9%).

Trial Locations (2)

10016

RECRUITING

NYU Langone Health, New York

10065

RECRUITING

The Rockefeller University, New York

All Listed Sponsors
collaborator

NYU Langone Health

OTHER

lead

Rockefeller University

OTHER